Treatment options for multiple myeloma patients with high-risk disease

Sikander Ailawadhi, Aisha Masood, Taimur Sher, Kena C. Miller, Margaret Wood, Kelvin Lee, Asher A Chanan Khan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Multiple myeloma is a heterogeneous malignant disorder with a variable clinical course suggestive of diverse biological factors that have important prognostic implications. Despite development of several new therapeutic agents and substantially effective novel combination regimens, myeloma remains an incurable disease. There is an emphasis to define new biologic parameters to accurately identify patients with aggressive disease biology. This will allow more informed treatment decisions based on the biology of the disease, resulting in further optimization of management strategies in specific patient subgroups. Among biological parameters of risk stratification, cytogenetics has emerged as arguably the most important dependable and clinically convenient. These are being increasingly utilized to develop therapeutic stratification in newer clinical trials. Appraisal of current data suggests that patients with high-risk cytogenetics have a worse prognosis. However, treatment with novel agents has changed this variable. There is emerging evidence that patients with aggressive disease biology are fairing better with innovative treatment regimens utilizing a combination of conventional and novel agents. This review focuses on current and emerging data about defining high-risk disease in multiple myeloma and the various therapeutic options for this group of patients.

Original languageEnglish (US)
JournalMedical Oncology
Volume27
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Multiple Myeloma
Cytogenetics
Therapeutics
Biological Factors
Clinical Trials

Keywords

  • Cytogenetics
  • FISH
  • High-risk
  • Multiple myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Treatment options for multiple myeloma patients with high-risk disease. / Ailawadhi, Sikander; Masood, Aisha; Sher, Taimur; Miller, Kena C.; Wood, Margaret; Lee, Kelvin; Chanan Khan, Asher A.

In: Medical Oncology, Vol. 27, No. SUPPL. 1, 06.2010.

Research output: Contribution to journalArticle

Ailawadhi, Sikander ; Masood, Aisha ; Sher, Taimur ; Miller, Kena C. ; Wood, Margaret ; Lee, Kelvin ; Chanan Khan, Asher A. / Treatment options for multiple myeloma patients with high-risk disease. In: Medical Oncology. 2010 ; Vol. 27, No. SUPPL. 1.
@article{96ef693f9e63417095a8a192ce42746b,
title = "Treatment options for multiple myeloma patients with high-risk disease",
abstract = "Multiple myeloma is a heterogeneous malignant disorder with a variable clinical course suggestive of diverse biological factors that have important prognostic implications. Despite development of several new therapeutic agents and substantially effective novel combination regimens, myeloma remains an incurable disease. There is an emphasis to define new biologic parameters to accurately identify patients with aggressive disease biology. This will allow more informed treatment decisions based on the biology of the disease, resulting in further optimization of management strategies in specific patient subgroups. Among biological parameters of risk stratification, cytogenetics has emerged as arguably the most important dependable and clinically convenient. These are being increasingly utilized to develop therapeutic stratification in newer clinical trials. Appraisal of current data suggests that patients with high-risk cytogenetics have a worse prognosis. However, treatment with novel agents has changed this variable. There is emerging evidence that patients with aggressive disease biology are fairing better with innovative treatment regimens utilizing a combination of conventional and novel agents. This review focuses on current and emerging data about defining high-risk disease in multiple myeloma and the various therapeutic options for this group of patients.",
keywords = "Cytogenetics, FISH, High-risk, Multiple myeloma",
author = "Sikander Ailawadhi and Aisha Masood and Taimur Sher and Miller, {Kena C.} and Margaret Wood and Kelvin Lee and {Chanan Khan}, {Asher A}",
year = "2010",
month = "6",
doi = "10.1007/s12032-010-9521-4",
language = "English (US)",
volume = "27",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "1357-0560",
publisher = "Humana Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Treatment options for multiple myeloma patients with high-risk disease

AU - Ailawadhi, Sikander

AU - Masood, Aisha

AU - Sher, Taimur

AU - Miller, Kena C.

AU - Wood, Margaret

AU - Lee, Kelvin

AU - Chanan Khan, Asher A

PY - 2010/6

Y1 - 2010/6

N2 - Multiple myeloma is a heterogeneous malignant disorder with a variable clinical course suggestive of diverse biological factors that have important prognostic implications. Despite development of several new therapeutic agents and substantially effective novel combination regimens, myeloma remains an incurable disease. There is an emphasis to define new biologic parameters to accurately identify patients with aggressive disease biology. This will allow more informed treatment decisions based on the biology of the disease, resulting in further optimization of management strategies in specific patient subgroups. Among biological parameters of risk stratification, cytogenetics has emerged as arguably the most important dependable and clinically convenient. These are being increasingly utilized to develop therapeutic stratification in newer clinical trials. Appraisal of current data suggests that patients with high-risk cytogenetics have a worse prognosis. However, treatment with novel agents has changed this variable. There is emerging evidence that patients with aggressive disease biology are fairing better with innovative treatment regimens utilizing a combination of conventional and novel agents. This review focuses on current and emerging data about defining high-risk disease in multiple myeloma and the various therapeutic options for this group of patients.

AB - Multiple myeloma is a heterogeneous malignant disorder with a variable clinical course suggestive of diverse biological factors that have important prognostic implications. Despite development of several new therapeutic agents and substantially effective novel combination regimens, myeloma remains an incurable disease. There is an emphasis to define new biologic parameters to accurately identify patients with aggressive disease biology. This will allow more informed treatment decisions based on the biology of the disease, resulting in further optimization of management strategies in specific patient subgroups. Among biological parameters of risk stratification, cytogenetics has emerged as arguably the most important dependable and clinically convenient. These are being increasingly utilized to develop therapeutic stratification in newer clinical trials. Appraisal of current data suggests that patients with high-risk cytogenetics have a worse prognosis. However, treatment with novel agents has changed this variable. There is emerging evidence that patients with aggressive disease biology are fairing better with innovative treatment regimens utilizing a combination of conventional and novel agents. This review focuses on current and emerging data about defining high-risk disease in multiple myeloma and the various therapeutic options for this group of patients.

KW - Cytogenetics

KW - FISH

KW - High-risk

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=77954086659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954086659&partnerID=8YFLogxK

U2 - 10.1007/s12032-010-9521-4

DO - 10.1007/s12032-010-9521-4

M3 - Article

AN - SCOPUS:77954086659

VL - 27

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 1357-0560

IS - SUPPL. 1

ER -